FindTrial
Sign In

Dexamethasone Intravitreal Implant for the Treatment of Macular Edema Due to Acute Retinal Necrosis

Dexamethasone Intravitreal Implant for the Treatment of Macular Edema Due to Acute Retinal Necrosis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200059276
Enrollment
Unknown
Registered
2022-04-27
Start date
2022-05-09
Completion date
Unknown
Last updated
2024-02-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Macular edema

Interventions

intervention:Dexamethasone intravitreal implant (dexamethasone 0.7mg)

Sponsors

The Fourth People’s Hospital of Shenyang
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Patients diagnosed as having macular edema due to acute retinal necrosis; 2.Intraocular fluid viral load is zero; 3.Ageing over or equal to 18 years old.

Exclusion criteria

Exclusion criteria: 1. With glaucoma or non-contact intraocular pressure =25mmHg; 2. Aphakia and/or absence of the Posterior capsule; 3. Any active intraocular or periocular infection; 4. Any concurrent intraocular condition that limits the potential to gain visual acuity upon treatment of the study.

Design outcomes

Primary

MeasureTime frame
Best corrected visual acuity;Central retinal thickness;—

Secondary

MeasureTime frame
Aqueous fluid viral load;—

Countries

China

Contacts

Public ContactLiu Xinshu

The Fourth People’s Hospital of Shenyang

liuxinshu@126.com+86 17740068751

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026